Spread­ing its wings in Chi­na with glob­al am­bi­tion, EpimAb snags $74M Se­ries B for bis­pe­cif­ic work

PHILADEL­PHIA — A Shang­hai-based biotech look­ing to make it big in the glob­al bis­pe­cif­ic boom has $74 mil­lion to both deep­en and broad­en its pres­ence in the clin­ic.

With the Se­ries B, EpimAb Bio­ther­a­peu­tics hopes to of­fer not on­ly proof that its plat­form tech works, but that it works across mul­ti­ple pro­grams. By the end of next year, it in­tends to have Phase I/II da­ta on 60 pa­tients for its lead as­set tar­get­ing EGFR and cMET as well as a sec­ond tri­al — for a dual check­point in­hibitor — well un­der way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER